Emergent BioSolutions (EBS) Revenue (2011 - 2026)

Emergent BioSolutions' Revenue history runs 16 years deep, the most recent figure standing at $156.1 million for Q1 2026.

• In Q1 2026, Revenue fell 29.75% year-over-year to $156.1 million; the TTM figure through Mar 2026 stood at $676.8 million (down 11.03% YoY), while the FY2025 annual figure was $742.9 million, down 28.81% from the prior year.
• Revenue was $156.1 million for Q1 2026 at Emergent BioSolutions, up from $148.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $337.9 million in Q2 2023 to a low of $50.0 million in Q2 2024.
• Historically, Revenue has averaged $229.7 million across 5 years, with a median of $239.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Revenue sank 85.2% in 2024, then jumped 181.8% in 2025.
• A 5-year view of Revenue shows it stood at $330.2 million in 2022, then decreased by 16.23% to $276.6 million in 2023, then slipped by 29.61% to $194.7 million in 2024, then retreated by 23.63% to $148.7 million in 2025, then increased by 4.98% to $156.1 million in 2026.
• The last three Revenue figures came in at $156.1 million (Q1 2026), $148.7 million (Q4 2025), and $231.1 million (Q3 2025), per Business Quant data.